Clinical trials: Microangiopathy
Pre-Eclampsia, Severe, HELLP Syndrome
Promising Bimarker Prediction of Outcome of HELLP Syndrome.
HELLP syndrome is a life-threatening obstetric complication usually considered to be a variant or complication of pre-eclampsia.
- Conditions
- Pre-Eclampsia, Severe, HELLP Syndrome, Microangiopathy
- Trial name
- NCT03246542
- Testing
- shistocytes percentage
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AYMAN ABDELKADER MOHAMED ABDELKADER
Thrombotic Microangiopathies
Defibrotide TMA Prophylaxis Pilot Trial
Thrombotic microangiopathy (TMA) is a common complication in the stem cell transplant population. Certain populations within the hematopoietic stem cell transplant (HSCT) population are at a higher risk than others.
- Trial name
- NCT03384693
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
aHUS - Atypical Hemolytic Uremic Syndrome
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy
This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.
- Trial name
- NCT05684159
- Testing
- NM8074
- Volunteers
- 12 people
- Sponsor
- NovelMed Therapeutics
Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
Safety and Efficacy of Eculizumab in High-risk TA-TMA
High-risk, complement-mediated, untreated transplant-associated thrombotic microangiopathy (hrTA-TMA) carries a very poor prognosis due to multiple organ dysfunction syndrome (MODS).
- Trial name
- NCT07707687
- Testing
- Eculizumab
- Where
- 8 sites in China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Type2 Diabetes Mellitus, Complications
Morbidity in Newly Diagnosed type2 Diabetes in Adults
It is a prospective,observational, cohort study The main purpose of the study is to assess the prevalence of diabetic chronic complications in newly diagnosed type 2 diabetics in suburban area of Algiers.
- Trial name
- MORNDIAB (NCT02002091)
- Testing
- no specific treatment
- Where
- Algeria
- Volunteers
- 327 people
- Sponsor
- University of Algiers
Microangiopathy, Kidney Transplant
Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant Centre
It is a retrospective-prospective, single-centre, non-pharmacological, retrospective tissue study carried out for scientific and health protection purposes.
- Trial name
- PT-TMA2022 (NCT06759961)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Microangiopathy, Microvascular Complications
Microangiopathy in Diabetes
This clinical trial aims to evaluate the use of a contactless and non-invasive technique to measure the properties of the skin's microcirculation and its regulatory functions in both healthy individuals and patients with…
- Trial name
- MIND (NCT07145567)
- Where
- Sweden
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Thrombotic Microangiopathies, Hematologic Diseases
A Safety and Efficacy Study of NAC in Patients With TA-TMA
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement…
- Trial name
- NCT03252925
- Testing
- N-Acetylcysteine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cerebral Cavernous Malformation, Cavernous Angioma
Biomarkers of CASH
The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans.
- Conditions
- Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy
- Trial name
- NCT04467489
- Testing
- observational
- Where
- 4 sites in United States
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
The goal of this clinical trial is to evaluate the efficacy and safety of Iptacopan as a second-line treatment for high-risk hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA).
- Trial name
- NCT07347990
- Testing
- iptacopan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Diabetic Foot
Obliterating Diabetic Microangiopathy of the Diabetic Foot
The purpose of this study will be the assessment of microangiopathy determined by the increase of capillary basement membrane thickness and decrease of capillary lumen area in the foot ulcer of 30 neuropathic and 30 neuroischemic…
- Trial name
- NCT02610036
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Multimedica
Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions.
- Conditions
- Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical, Hemolytic-Uremic Syndrome
- Trial name
- COMPETE (NCT04745195)
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Maastricht University Medical Center
Coronary Artery Disease
Single Blind Randomized Study to Determine the Sensitivity and Specificity of 2 Non-invasive Markers of Early Coronary Disease
Diagonal ear lobe crease and microcirculatory disorder in the conjunctiva are both non invasive methods documented in the literature as early signs of coronary artery disease.
- Trial name
- NCT01742156
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Atypical Hemolytic Uremic Syndrome
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study participants with aHUS.
- Trial name
- NCT05935215
- Testing
- Iptacopan
- Where
- 31 sites in China, France and 6 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
This is a multicenter, single arm, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of iptacopan in participants with aHUS.
- Trial name
- NCT05795140
- Testing
- Iptcaopan 200 mg
- Where
- 9 sites in Brazil, China and 4 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
TTP - Thrombotic Thrombocytopenic Purpura
Italian iTTP Registry
ItaliTTP is an observational, prospective, single-arm, national, multicenter, non-pharmacological cohort study aimed at better defining and understanding the natural history, disease severity, and clinical outcomes of patients…
- Trial name
- NCT06376786
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- Fondazione Luigi Villa
Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Problems of compatibility between a mother and her child are frequent. The most well-known case can be illustrated by the fetomaternal blood group incompatibility (rhesus factor) which can induce severe anemia of the fetus.
- Conditions
- Glomerulonephritis, Membranous, Neonatal Diseases and Abnormalities, Hemochromatosis
- Trial name
- NCT00199628
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges
Ocular Complications in AIDS Patients, Such as Fundus Opportunistic Infections, Microangiopathy, and Uveitis
Analysis of Ocular Complications of AIDS Patients in Ophthalmic Consultation
Through a cross-sectional descriptive analysis of ophthalmic consultation of AIDS patients in the past 3 years, the basic characteristics of patients were described according to whether there was fundus change, and the clinical…
- Trial name
- NCT06250881
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhongnan Hospital
Thrombotic Microangiopathies
The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy
Study rationale: Viral infections, such as CMV, are a risk factor for TA-TMA (transplantation-associated TMA). Viral infections increase interferon (IFN) levels and high IFN levels are associated with thrombotic microangiopathy…
- Trial name
- ROSARIO (NCT07705789)
- Testing
- blood draw, urine collection
- Where
- 3 sites in Belgium
- Volunteers
- 40 people
- Sponsor
- Sofie Dhaese
Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy
A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy
This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).
- Conditions
- Non-proliferative Diabetic Retinopathy (NPDR), Diabetic Retinal Microangiopathy, Retinal Microaneurysms, Diabetic Retinopathy
- Trial name
- NCT07198815
- Testing
- Investigational Eye Drops (NPDR-01)
- Volunteers
- 10 people
- Sponsor
- Sichuan Academy of Medical Sciences